Efficacy
The median follow up was 17 months, the HR for progression-free survival was 0.72 (95% CI, 0.58 to 0.90, p=0.0031) indicating a 28% reduction in the progression free event. Median PFS for GC was 8.6 months (95% CI, 7.9 to 9.7 months) and 5.8 months for carboplatin (95% CI, 5.2 to 7.1 months).r
Progression-free survival according to therapy in the trialr
© Journal of Clinical Oncology 2006
Median overall survival was 18.0 months (95% CI, 16.2 to 20.2 months) for GC arm and 17.3 months (95% CI, 15.2 to 19.3 months) for the carboplatin arm. The study was not powered to detect significant differences in overall survival. Response rate was significantly higher in the GC arm than the carboplatin arm (47.2% v 30.9%; p=0.0016; Table 4). Median duration of response was 8.4 months (95% CI, 7.6 to 9.6 months) in the GC arm and 7.3 months (95% CI, 5.9 to 8.2 months) in the carboplatin arm.
Overall survival according to therapy in the trialr
© Journal of Clinical Oncology 2006
Responser
© Journal of Clinical Oncology 2006